glp 1 agonists for type 2 diabetes GLP1 Receptor vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Could GLP-1 Receptor Agonists Help
Description
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
These preclinical insights have been validated in large-scale clinical trials.The FLOW trial (n = 3,533) showed that once-weekly subcutaneous administration of semaglutide (1.0 mg) significantly reduced the risk of a renal composite endpointincluding 50% decline in eGFR, renal failure, or cardiovascular deathby 24% in patients with T2DM and chronic kidney disease (CKD) (HR = 0.76, 95% CI: 0.660.88
Considering that OSAS patients often present with multiple comorbiditiessuch as hypertension, coronary artery disease, and diabetesfurther large-scale, long-term follow-up studies are needed to clarify tirzepatides safety in multimorbid populations (63, 64)
E.TolhurstG.HabibA
beta-cell failure in diabetes and preservation by clinical treatment
By dampening inflammation and modulating microglial activity, GLP-1 RAs create a neuroprotective environment that supports neuronal survival [78]
